ABSI Stock Risk & Deep Value Analysis
Absci Corp
Healthcare • Biotechnology
DVR Score
out of 10
What You Need to Know About ABSI Stock
We analyzed Absci Corp using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran ABSI through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Aggressive. Here's what we found.
ABSI Risk Analysis & Red Flags
What Could Go Wrong
The company is burning approximately $23.5M per quarter with a current cash runway of only about 18 months ($144.3M cash / $94M annual burn). A continued lack of significant, non-dilutive partnership revenue or further clinical setbacks will necessitate a highly dilutive capital raise in late 2027 or early 2028, potentially leading to a substantial drop in share price and prolonged underperformance.
Risk Matrix
Overall
Aggressive
Financial
High
Market
Medium
Competitive
Medium
Execution
High
Regulatory
Low
Red Flags
- ⚠
FY2025 revenue declined 38% YoY, signaling a clear operational stumble.
- ⚠
Q4 2025 revenue missed consensus by 53% and EPS missed by $0.07.
- ⚠
ABS-101 program halted due to disappointing Phase 1 data.
- ⚠
Cash burn increased by 29% YoY, leading to a projected 18-month cash runway.
- ⚠
P/S ratio of 167.1x is extremely elevated for a company with declining revenue and no clear path to profitability.
Upcoming Risk Events
- 📅
Failure to secure new partnerships or revenue streams in 2026
- 📅
Further acceleration of cash burn beyond $94M TTM
- 📅
Highly dilutive capital raise due to dwindling cash runway
When to Reconsider
- 🚪
Cash runway drops below 12 months without a clear, non-dilutive funding plan.
- 🚪
Announcements of further significant revenue declines or program halts.
- 🚪
Quarterly revenue consistently below $0.5M for two consecutive quarters.
Unlock ABSI Risk Analysis & Red Flags
Create a free account to see the full analysis
What Does Absci Corp (ABSI) Do?
Market Cap
$468.00M
Sector
Healthcare
Industry
Biotechnology
Employees
156
Absci Corporation operates as a data-first generative artificial intelligence (AI) drug creation company in the United States. The company combines AI with scalable wet lab technologies to design differentiated antibody therapeutics. Its preclinical development programs include ABS-101 for the treatment of inflammatory bowel disease; ABS-201 for treating androgenic alopecia; ABS-301 for the treatment of immuno-oncology; and ABS-501 for treating oncology. Absci Corporation has collaboration agreements with PrecisionLife, Memorial Sloan Kettering Cancer Center, Twist Bioscience, Owkin, Oracle Corporation, and Advanced Micro Devices, Inc. for joint research and development activities. The company was founded in 2011 and is headquartered in Vancouver, Washington.
Visit Absci Corp WebsiteInvestment Thesis
Absci represents a highly speculative, high-risk bet on the transformative potential of its AI-powered drug discovery platform. Despite significant financial challenges and a recent clinical setback, the underlying technology, strategic vision for accelerating drug development, and potential for high-margin licensing/milestone revenue could lead to substantial upside if they secure pivotal, high-value partnerships and successfully bring pipeline candidates to market. The 10x potential hinges on a complete turnaround of its current financial trajectory driven by successful platform validation.
Is ABSI Stock Undervalued?
Unlock the full AI analysis for ABSI
Get the complete DVR score, risk analysis, and more
Unlock the full report
Create a free account to see the DVR score, risk flags, and AI analysis.
ABSI Price Targets & Strategy
12-Month Target
$7.00
Bull Case
$10.00
Bear Case
$1.50
Valuation Basis
Analyst consensus average of $7.00 is highly speculative, implying a future P/S multiple >20x on significantly increased, but currently uncertain, future partnership and milestone revenue streams, assuming successful execution and new programs. This is a qualitative target based on future potential, not current fundamentals.
Entry Strategy
Dollar-cost average on dips towards $2.20-$2.30 (near CIO's purchase price and recent support). Avoid large single positions given high risk.
Exit Strategy
Take profits incrementally at analyst targets of $7.00-$8.00. Implement a strict stop-loss if price drops below $2.00, signaling further erosion of confidence.
Portfolio Allocation
1-3% for aggressive risk tolerance, only as a highly speculative bet.
Price Targets & Strategy
Upgrade to Premium for price targets and entry/exit strategies
Does ABSI Have a Competitive Moat?
Sign in to unlockMoat Rating
🛡️ Narrow
Moat Trend
Stable to Eroding. While the technology is strong, the recent clinical setback and revenue decline raise questions about the platform's immediate efficacy and ability to generate superior drug candidates compared to rivals, potentially making future partnerships harder to secure.
Moat Sources
2 Identified
The moat's durability relies heavily on Absci's ability to demonstrate consistent success in drug discovery through its platform, securing long-term, high-value partnerships, and continually advancing its proprietary AI and data. Failure to do so could lead to competitors closing the technological gap.
Moat Erosion Risks
- •Rapid advancements by competing AI drug discovery platforms that prove more effective or efficient.
- •Failure to translate platform capabilities into successful clinical candidates and revenue-generating partnerships.
- •Dependence on partner investment and risk tolerance for novel AI approaches.
ABSI Competitive Moat Analysis
Sign up to see competitive advantages
ABSI Market Intelligence
Sentiment & Insider Activity
Social Sentiment
Neutral to Bearish. Recent financial misses and clinical setbacks likely weigh on retail sentiment, despite the underlying AI narrative.
Institutional Sentiment
Neutral to Positive. Analysts maintain 'Moderate Buy' ratings despite estimate cuts, indicating long-term conviction, but 186 institutional owners with significant holdings may be evaluating recent developments.
Insider Activity (Form 4)
Chief Innovation Officer Andreas Busch purchased 100,000 shares at $2.29/share on March 12, 2026, increasing his position by 31%. CEO Sean McClain received routine RSU and option grants in March 2026.
Options Flow
Normal options activity; no specific unusual activity reported.
Earnings Intelligence
Next Earnings
Estimated early-May 2026 (for Q1 2026)
Surprise Probability
Medium (High probability of continued revenue miss given Q4 trend, but low EPS estimates could be marginally beaten or missed)
Historical Earnings Pattern
Likely volatile reactions, with significant sell-offs on misses or negative guidance, given the early-stage and high-risk nature of the business.
Key Metrics to Watch
Competitive Position
Top Competitor
Not specified in research, but likely other AI-driven drug discovery platforms (e.g., Exscientia, Recursion Pharmaceuticals).
Market Share Trend
Undetermined; early-stage company vying for collaborations within a nascent but highly competitive segment.
Valuation vs Peers
Likely trading at a significant premium on P/S due to AI narrative, despite underperforming revenue compared to more established biotechs or even other early-stage AI peers that show revenue growth.
Competitive Advantages
- •Proprietary AI-powered 'Integrated Drug Creation' platform
- •Unique combination of generative AI and high-throughput wet-lab experiments
- •Proprietary biological data generation for AI training
Market Intelligence
Get sentiment, earnings intel, and peer analysis with Premium
What Could Drive ABSI Stock Higher?
Near-Term (0-6 months)
- •Q1 2026 Earnings (No specific date, likely May 2026)
- •Announcement of new, significant drug discovery partnerships
Medium-Term (6-18 months)
- •Progression of existing collaboration programs to advanced milestones
- •Positive preclinical or Phase 1 data from new internal programs (not ABS-101)
Long-Term (18+ months)
- •Broad adoption of Absci's AI platform across the pharmaceutical industry
- •Successful commercialization of a drug discovered using Absci's platform
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
What's the Bull Case for ABSI?
- ✓
Announcement of multiple new, significant collaboration agreements (>$5M upfront payment each)
- ✓
Clear progress on alternative internal drug programs beyond ABS-101, with positive preclinical or early clinical data.
- ✓
Reduction in the quarterly cash burn rate or positive free cash flow guidance.
Bull Case Analysis
See what could go right with Premium
Competing with ABSI
See how Absci Corp compares to related companies
| Company | Market Cap | DVR Score | P/E | Revenue | Profit Margin | Rev Growth | |
|---|---|---|---|---|---|---|---|
Absci Corp ABSI | $468.0M | 4.3 | — | $2.8M | 0.0% | -37.8% | |
AbbVie Inc ABBV | $403.8B | 0.1 | 171.8 | — | — | — | Compare → |
Johnson & Johnson JNJ | — | 1.0 | — | — | — | — | Compare → |
Eli Lilly and Co LLY | $965.0B | 0.5 | 52.6 | — | — | — | Compare → |
Pfizer Inc PFE | $150.6B | 0.2 | 19.4 | $62.6B | 12.4% | -1.6% | Compare → |
UnitedHealth Group Inc UNH | $276.2B | 0.3 | 22.9 | $113.7B | 2.7% | 1181.0% | Compare → |
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
How Absci Corp Makes Money
Absci Corp develops and utilizes an innovative 'Integrated Drug Creation™' platform, which combines generative artificial intelligence with high-throughput wet-lab experiments, to accelerate the discovery and development of novel protein-based drug candidates. They partner with pharmaceutical companies to leverage their AI platform to design and optimize new therapeutic proteins, aiming to reduce the time and cost typically associated with traditional drug discovery. Their value proposition is to make drug creation faster, smarter, and more effective for their partners.
Read Full Business Model BreakdownFAQ
What is the DVR Score for Absci Corp (ABSI)?
As of April 11, 2026, Absci Corp has a DVR Score of 4.3 out of 10, placing it in the "Proceed with Caution" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.
What is the market capitalization of Absci Corp?
Absci Corp's market capitalization is approximately $468.0M. The company operates in the Healthcare sector within the Biotechnology industry.
What ticker symbol does Absci Corp use?
ABSI is the ticker symbol for Absci Corp. The company trades on the NMS.
What is the risk level for ABSI stock?
Our analysis rates Absci Corp's overall risk as Aggressive. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.
Is Absci Corp's revenue growing?
Absci Corp has reported revenue growth of -37.8%. Revenue has been declining, which warrants closer examination.
Is ABSI stock profitable?
Absci Corp has a profit margin of 0.0%. The company is currently unprofitable.
How often is the ABSI DVR analysis updated?
Our AI-powered analysis of Absci Corp is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on April 11, 2026.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for ABSI (Absci Corp) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.